Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Total Inventories : $0.00 Mil (As of Mar. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Total Inventories?

Checkmate Pharmaceuticals's total inventories for the quarter that ended in Mar. 2022 was $0.00 Mil. Checkmate Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Checkmate Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $2.22.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Checkmate Pharmaceuticals Total Inventories Historical Data

The historical data trend for Checkmate Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Total Inventories Chart

Checkmate Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Total Inventories

Checkmate Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Total Inventories	Get a 7-Day Free Trial									-	-	-	-	-

Checkmate Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Checkmate Pharmaceuticals (NAS:CMPI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Checkmate Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is

	Net-Net Working Capital Per Share (Q: Mar. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(60.033	+	0.75 * 0	+	0.5 * 0	-	11.942
-	0	-	0)	/	21.6306
=	2.22

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Checkmate Pharmaceuticals's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2022 )	/	Cost of Goods Sold (Q: Mar. 2022 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Checkmate Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2022 )	/	Average Total Inventories (Q: Mar. 2022 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Checkmate Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2022 )	/	Revenue (Q: Mar. 2022 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Checkmate Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142

Website

https://www.checkmatepharma.com

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

Executives

Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash	director, officer: Chief Executive Officer	C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg	director, officer: Chief Scientific Officer	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski	officer: Chief Financial Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger	director, officer: President and CEO	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono	director	C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff	director	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan	officer: Chief Operating Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary	officer: Chief Business Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6